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Abstract
Background: Cardiovascular risk functions fail to identify more than 50% of patients who develop cardiovascular
disease. This is especially evident in the intermediate-risk patients in which clinical management becomes difficult.
Our purpose is to analyze if ankle-brachial index (ABI), measures of arterial stiffness, postprandial glucose,
glycosylated hemoglobin, self-measured blood pressure and presence of comorbidity are independently associated
to incidence of vascular events and whether they can improve the predictive capacity of current risk equations in
the intermediate-risk population.
Methods/Design: This project involves 3 groups belonging to REDIAPP (RETICS RD06/0018) from 3 Spanish
regions. We will recruit a multicenter cohort of 2688 patients at intermediate risk (coronary risk between 5 and
15% or vascular death risk between 3-5% over 10 years) and no history of atherosclerotic disease, selected at
random. We will record socio-demographic data, information on diet, physical activity, comorbidity and
intermittent claudication. We will measure ABI, pulse wave velocity and cardio ankle vascular index at rest and after
a light intensity exercise. Blood pressure and anthropometric data will be also recorded. We will also quantify lipids,
glucose and glycosylated hemoglobin in a fasting blood sample and postprandial capillary glucose. Eighteen
months after the recruitment, patients will be followed up to determine the incidence of vascular events (later
follow-ups are planned at 5 and 10 years). We will analyze whether the new proposed risk factors contribute to
improve the risk functions based on classic risk factors.
Discussion: Primary prevention of cardiovascular diseases is a priority in public health policy of developed and
developing countries. The fundamental strategy consists in identifying people in a high risk situation in which
preventive measures are effective and efficient. Improvement of these predictions in our country will have an
immediate, clinical and welfare impact and a short term public health effect.
Trial Registration: Clinical Trials.gov Identifier: NCT01428934
Keywords: Risk assessment, cardiovascular diseases, primary prevention, primary health care.
Background
In Spain, as in most Mediterranean countries, death
rates from cardiovascular diseases have traditionally
been lower compared with those in Anglo-Saxon and
northern and central Europe [1]. However, they are still
a priority public health problem because vascular dis-
eases contribute to 30% of total mortality in developed
countries, 56 million deaths worldwide, of which more
than 125, 000 are in Spain [2]. The European guideline
for vascular prevention [3] recommends that prevention
strategies should include three main components: 1) a
population strategy to try to change lifestyle, social,
environmental and economic factors which are highly
related to the disease occurrence 2) a secondary preven-
tion strategy to reduce recurrences, complications rates
and improve the disease prognostic and 3) a primary
prevention strategy in high-risk population in which dif-
ferent interventions are more efficient than in general
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element is to identify these individuals through the use
of risk functions. This strategy has some limitations at
present, since sometimes the performance of such func-
tions is insufficient, especially in patients classified as
intermediate-risk (5-15% risk at 10 years) [4]. Several
attempts to improve risk functions by using new risk
factors markers have not increased their predictive abil-
ity, because of the autocorrelation of these emerging fac-
tors with classical risk ones [5,6]. With the available
evidence we cannot assess the balance between risks
and benefits of the studied factors for its widespread use
in asymptomatic men and women with no history of
coronary disease [7]. The general conclusion is that this
issue is a priority in vascular prevention research.
There are three opportunity areas to improve the risk
estimation in intermediate-risk population:
1. The measure of subclinical atherosclerosis: Markers
of atherosclerotic burden ar et h em o s tr e l i a b l ec a n d i -
dates to identify patients at increased risk of the inter-
mediate-risk group [8]. Values below 0.9 on the ankle
brachial index (ABI) are associated with an increased
risk of coronary heart disease events and mortality,
regardless of calculated risk by the Framingham equa-
tion [9], even in asymptomatic patients [10]. Therefore,
ABI at baseline provides extra prognostic information
which is not provided by the measurement of conven-
tional risk factors alone. In our country, results have
also been reported to confirm this assumption, since
ABI values < 0.9 have been found to be relatively com-
mon in asymptomatic patients with coronary risk at 10
years less than 10% [11].
Arterial stiffness is also a parameter that is considered
as a possible good marker of cardiovascular risk [12,13].
Traditionally, it has been quantified by pulse wave velo-
city (PWV). The Cardio Ankle Vascular Index (CAVI) is
an index representing the stiffness of the aorta, femoral
artery and tibial artery [14]. Some authors suggest that
CAVI measurement, which is independent of blood
pressure and has an adequate reproducibility for clinical
use, is more useful as a marker of arterial stiffness than
PWV [15].
2. The incorporation of more detailed and accurate
assessment of traditional risk factors: The glycated
h e m o g l o b i n( H b A 1 c )i sam o r ea c c u r a t ea n ds t a b l e
measure than fasting glucose concentration [16]. It is
more and more suggested that HbA1c concentration is
not only a useful marker in patients with DM, but can
also be useful to identify patients at higher risk of
developing cardiovascular problems in the general
population. In this regard, a recent study shows that
high levels of HbA1c are associated with the occur-
rence of cardiovascular disease in nondiabetic patients
[17] and high values of this type of hemoglobin are
common in general adult population with no history of
diabetes [18].
Postprandial glucose concentration has negative effects
on the arterial wall and several studies have shown that
a good control of postprandial glucose can revert to a
reduction of cardiovascular events and mortality [19,20].
Self-measured blood pressure has a significant correla-
tion with cardiovascular morbidity and mortality [21]
and its control has some advantages such as being easily
accessible and comfortable for the patient. It also has
the possibility of performing multiple measurements on
non-medical environment, so that white coat effect is
avoided.
3. The incorporation of a comprehensive and contex-
tualized evaluation of the patient taking into account his
co-morbidity: Several studies have highlighted the
importance of the presence of certain chronic diseases
in vascular diseases development. There are arguments
supporting that the presence of chronic obstructive pul-
monary disease [22], atrial fibrillation [23], renal disease
[23] and depression [24] among others are associated,
independently, with an increased incidence of vascular
disease. Just as the high score on composite indices of
co-morbidity, has been associated with a worse prog-
nosis of vascular diseases [25]. This suggests that this
information may be useful for risk stratification, even in
primary prevention.
Thus, these three lines of analysis and the proposed
variables have significant scientific support as candidates
to improve the population risk classification. They are
also measures that can be easily and economically
obtained and can be implemented in primary care,
which is suitable for the population screening. The
demonstration of the usefulness of some of these factors
in re-stratify the population’sr i s kw i l lh a v eam a j o r
impact on the primary prevention of the vascular dis-
eases with all that this implies at the Public Health level.
All this justifies the proposal to analyze their contribu-
tion to improve the predictive ability of the existing risk
functions.
Objectives
To analyze whether the ABI and arterial stiffness mea-
sures (pulse wave velocity and cardio ankle vascular
index) are associated independently with the incidence
of vascular events and whether they can help to improve
the predictive ability of risk equations based on tradi-
tional risk factors in intermediate-risk population.
To analyze whether the postprandial capillary glucose,
glycated hemoglobin, and self-blood pressure measure-
ment are associated independently with the incidence of
vascular events and whether they can help to improve
the predictive ability of risk equations based on classical
risk factors in intermediate-risk population.
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sured by composite indices (Charlson Index, Cumulative
Illness Rating score) is associated independently with
the incidence of vascular events and whether they can
help to improve the predictive ability of risk equations
based on classical risk factors in intermediate-risk
population.
Methods/Design
Design
Multicentre prospective cohort study with a follow-up
to 1.5, 5, and 10 years from the participant inclusion in
the study.
Subjects
Study population
Population aged between 35 to 74 years who have an
intermediate cardiovascular risk, defined as coronary
risk between 5% -15% at 10 years according to the Fra-
mingham adapted risk equation (because of the low
incidence of coronary heart disease in our country)
[26] or vascular mortality risk between 3-5% at 10
years according to the SCORE equation [27]. Exclusion
criteria: terminal illness or institutionalization at the
appointment time or a personal history of athero-
sclerotic disease. Sample selection: There will be a ran-
dom sample of population aged 35 to 74 (both
included) which have an intermediate cardiovascular
risk. This is a multicenter project in the context of the
Instituto Carlos III Preventive and Health Promotion
Research Network (RedIAPP) (RETICS RD06/0018).
Sample recruitment will be carried out in Health Cen-
ters belonging to 3 groups of the 3 network regions.
Candidate patients will be cited by telephone at their
health centre and invited to participate by signing an
informed consent.
Sample size
The ABI < 0.9 population proportion with no history of
vascular disease has been taken into account because
ABI is the risk factor among those studied that we
anticipate will have a lower prevalence. It is expected
that in one year and a half of follow up 3% of the parti-
cipants will present a vascular event. Therefore, accept-
ing a 0.05 alpha risk and a 0.2 beta risk in a bilateral
contrast, 336 subjects are needed in the exposed group
and 2352 in the non-exposed group (2688 total) to
detect a minimum relative risk of 2. We assumed an
incidence rate in the unexposed group of 3%. Estimating
a 25% of loss rate until 3360 participants will be over-
sampled. Poisson approximation has been used. The
estimated relative risk is based on previous observational
studies in which patients of the risk group had twice the
incidence of vascular disease if they had an ABI < 0.9
[9]. In Catalonia node centers 1900 participants are
expected to be recruited and 400 participants in each of
the other two nodes. Professional nurses assigned to
each health center will perform the physical examination
and questionnaires. They will explain how to record the
self-measurement of blood pressure and capillary blood
glucose and the candidates will be cited later to collect
this information. At the same time they will be sched-
uled for a fast blood test.
Data collection method
A case report form has been created for the study. For
telephone follow-up a questionnaire has been created to
record death or vascular events.
Variables
It will be recorded the demographic baseline informa-
tion of age, sex, marital status and employment status.
Educational level and social class will also be recorded
as potential confounding factors. Educational level will
be grouped into three categories: high level (patients
with university education), middle level (secondary edu-
cation until age 16 -18) and low level (patients who
haven’t received any education or have only completed
primary school). Social class will be measured by the
Spanish National Occupation Classification. Drugs
which may be related to cardiovascular diseases will be
recorded (antiplatelet agents, warfarin, oral contracep-
tives, hormonal therapy, lipid lowering agents, antihy-
pertensive and antidiabetic agents).
Co-morbidity study
Clinical history, date of diagnosis and treatment of
hypertension, diabetes, atrial fibrillation, chronic
obstructive pulmonary disease, renal disease and
depression will be collected. The Charlson Comorbid-
ity Index, which contains 19 comorbidity categories,
will be calculated. Each index category has an asso-
ciated weight, taken from the original Charlson’sd o c u -
ment [28], which is based on the adjusted mortality
risk per year. The overall comorbidity score reflects
the greater cumulative probability of mortality per
year. The higher the score the more severe the comor-
bidity burden is. The Cumulative Illness Rating Scale
(CIRS) will also be calculated. This index scores medi-
cal problems categorized into 14 organ systems from 0
to 4 points [29]. The general rules for the severity rat-
ing are the following: (0) no problem affecting this sys-
tem or a problem of the past without clinical
relevance, (1) current mild problem or severe problem
of the past, (2) moderate disability or morbidity and/or
requires a first-line therapy, (3) serious problem and/or
significant disability and/or chronic conditions which
are difficult to control (complex treatment regimen),
(4) extremely serious problem and/or required
immediate treatment and/or organ failure and/or
severe functional impairment.
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A validated food frequency consumption questionnaire
[ 3 0 ]a n dav a l i d a t e dq u e s t i o n n a i r ea b o u tt h ea d h e r e n c e
in Mediterranean diet [31] will be used.
Physical activity
The adapted Minnesota’s leisure time activity question-
naire will be used, whose use has been validated in the
Spanish population [32]. The average daily physical
activity during leisure time of the last year will be
reported.
Tobacco consumption
A questionnaire of 4 standard questions adapted from
the WHO MONICA study will be used. The carbon
monoxide concentration will be measured by a co-oxi-
meter and the participants will be asked when the last
cigarette was smoked.
Alcohol consumption
A questionnaire about alcohol consumption in the last 7
days will be included through a detailed questionnaire
about alcohol types and volume.
Intermittent claudication
The Edinburgh validated questionnaire will be used [33].
Existence of asymptomatic PAD will be considered
when ABI values are < 0.9 and no intermitent claudica-
tion are registered in the questionnaire.
Electrocardiogram
A 12-derivation digital electrocardiograph CardioSoft
®
(General Electrics) will be used to test the participants
at rest.
Blood pressure measurements
Blood pressure measured by nurse will be made in sit-
ting position after 5 minutes of rest and it will be per-
formed 3 times separated by 2 minutes in each arm. An
automatic and validated device will be used (OMRON
705). The subject should avoid doing any type of exer-
cise at least one hour before the measurements. He or
she should also avoid eating or drinking much, smoking
and taking medication that could directly affect the BP
(except in hypertension treated patients). Blood pressure
self-measurement will be made by participants at their
home for three days. They will make 2 blood pressure
measurements separated by 2 minutes in the morning
and in the evening, before having breakfast and dinner,
respectively [34].
Ankle-brachial index and arterial stiffness
They will be measured using Vasera device VS-1500
®
(Fukuda Denshi). For the study, the lowest ankle-brachial
index obtained will be considered. The pulse wave velocity
(PWV) will be calculated, as well as Cardio Ankle Vascular
Index (CAVI), which gives a more accurate calculation of
the atherosclerosis degree. CAVI integrates cardiovascular
elasticity derived from the aorta to the ankle pulse velocity
through an oscillometric method and it is used as a good
measure of vascular stiffness. It doesn’td e p e n do nb l o o d
pressure and the information that it gives may help to pre-
vent peripheral vascular occlusions [14]. Ankle-brachial
index, blood pressure and CAVI will be measured at rest
and after light intensity exercise in order to evaluate
whether there are changes in the measurements that can
predict cardiovascular risk better. Participants will cycle
on a static bike for 5 minutes at 70 wats of power before
the measurement.
Anthropometric measurements
Weight will be measured with a precision scale, which
will be weekly calibrated. The return to zero will be
checked after every measurement. Size will be measured
vertically. Subjects should remove their shoes, jackets,
coats etc. Waist circumference: the midway between the
lowest rib and the iliac crest will be localized.
Laboratory data
The blood sample will be taken after 12 hours fasting.
Cholesterol and triglycerides concentration will be deter-
mined by enzymatic methods and HDL cholesterol after
apo B containing lipoprotein precipitation. LDL choles-
terol will be determined by the Friedewald formula. Glu-
cose concentration (mg/dl), glycated hemoglobin (%) and
creatinine will also be determined, as well as urine albu-
min, to calculate the albumin/creatinine index. Postpran-
dial glucose (mg/dl) will be self-measured by patients at
home 2 hours after meals (breakfast, lunch and dinner)
for one day using an Accu-chek
® glucometer.
Vascular events in the follow-up
There will be a telephone follow-up to the 1.5, 5 and 10
years to verify the vital status and the existence of hospi-
tal admissions due to vascular health problems. The
information of each case will be confirmed after a review
of hospital discharge reports and the verification of the
diagnostic criteria by a consensus of at least 2 investiga-
tors. Fatal and non fatal coronary heart disease (myocar-
dial infarction or angina pectoris) will be considered.
Cases will be classified according to symptoms, electro-
cardiogram, and myocardial necrosis markers. Fatal cases
will be classified through the death certificate or autopsy
findings. Angina pectoris only will be considered if there
are changes in the ECG or a positive stress test. Stroke
will be considered when neurologic deficit lasting more
than 24 h attributable to a diagnosis of a focal cerebral
ischemia is confirmed by an imaging test (CT or MRI).
Peripheral arterial disease will be considered if there is a
diagnostic made by arteriography or Doppler (ankle-bra-
chial index below 0.9) or lower limb amputation or ulcer
or gangrene attributable to an ischemic deficit.
Statistical analysis
Percentages will be used to describe categorical variables.
Continuous variables will be described with the mean and
standard deviation or with the median and the interquar-
tile range as appropriate. Homogeneity among centers will
Martí et al. BMC Cardiovascular Disorders 2011, 11:61
http://www.biomedcentral.com/1471-2261/11/61
Page 4 of 6be proved by a Chi-square test or Kruskal-Wallis test
depending on the probability distribution of variables. A
multivariate analysis by Cox proportional risk models will
be performed to examine the contribution of the studied
risk factors adjusted by traditional risk factors (age, sex,
total cholesterol and HDL cholesterol, smoking status, dia-
betes and blood pressure).
Limitations and biases of the study
One of the major difficulties of the study is to achieve a
good participation rate. The research team has experi-
ence in cohort studies with good success rates (above
70%). Some of the measurements which must be per-
formed are laborious and require a previous training of
people who will perform it to ensure accurate, compar-
able and quality results. This will be fixed by the pre-
vious training and a pilot test of 100 participants.
Ethical considerations
The study has received ethical approval from the Research
Ethics Committee of the Institut d’Investigació en Atenció
Primària Jordi Gol (Primary Care Research Institute Jordi
Gol). Participants will be informed about the examinations
performed, they will receive an information document and
they will be asked for the informed consent prior to their
inclusion. The principles of human experimentation, as
the Helsinki Agreement, will be respected. Access to the
information obtained from any analysis will be guaranteed.
Confidentiality rules will be respected and the participants
will be informed about the 5
th Article of the15/1999 Span-
ish organic Law, about the regulation of the automatic
processing of personal data (personal data may be automa-
tically processed and the participants have the rights to
consult, modify or delete their personal data file).
Discussion
Primary prevention of cardiovascular diseases is a priority
in public health policy of developed and developing coun-
tries. The fundamental strategy consists in identifying peo-
ple in a high risk situation in which preventive measures
are effective and efficient. However, specificity and sensi-
tivity of risk equations are modest, which means that
approximately 50% of the patients who are likely to
develop a vascular event and would benefit from preven-
tive measures are not considered at high risk. While 30%
of the subjects considered at risk don’t really benefit from
preventive measures. Moreover, decisions which imply
thousands of people and can determine drug treatment
indications are taken every day in primary care centers.
These decisions are based mostly on the result of estima-
tions about the probability to develop a vascular disease in
10 years. Improvement of these predictions in our country
will have an immediate, clinical and welfare impact and a
short term public health effect. The efficiency and
therefore the best use of the resources will benefit our
public health system immediately. The global relevance of
the issue about improving predictive risk models, the
novelty of including determinate risk factors in a southern
Europe population and to build equations for risk sub-
groups amply justifies the implementation of this project.
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